Changes in type VI collagen degradation reflect clinical response to treatment in rheumatoid arthritis patients treated with tocilizumab.
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
29
09
2023
accepted:
16
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation in multiple articular joints, causing pain, joint damage, and loss of joint function. Despite the successful development of disease-modifying therapies, the heterogeneity of RA means that a significant proportion of patients respond poorly to treatment. This highlights the need for personalized medicine and predictive biomarkers to optimize treatment efficacy, safety, and cost. This study aimed to explore the relationship between type VI collagen (Col VI) remodeling and clinical response to anti-IL-6 receptor treatment. Type VI collagen degradation was quantified using the C6M biomarker, a fragment of type VI collagen degraded by MMPs. Longitudinal differences in average biomarker levels between placebo and treatment groups were estimated using linear mixed models. The predictive capacity of the marker based on change from baseline to 4 weeks was analyzed using logistic regression. Both 4 mg and 8 mg doses of Tocilizumab (TCZ) reduced serum C6M concentrations compared to the placebo. Furthermore, C6M levels were more reduced in patients responding to treatment compared to early non-responders. A lower early reduction in C6M was associated with reduced odds of ACR treatment response and lowered disease activity. These findings suggest that quantifying type VI collagen turnover may aid in identifying patients less likely to respond to treatment, indicating a new path towards optimizing patient care. Further studies are needed to validate these findings and explore the underlying mechanisms driving the observed relationships.
Identifiants
pubmed: 38167226
doi: 10.1186/s13075-023-03242-0
pii: 10.1186/s13075-023-03242-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Informations de copyright
© 2023. The Author(s).
Références
Bay-Jensen AC, Platt A, Byrjalsen I, Vergnoud P, Christiansen C, Karsdal MA. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin Arthritis Rheum. 2014;43(4):470–8. https://doi.org/10.1016/j.semarthrit.2013.07.008 .
doi: 10.1016/j.semarthrit.2013.07.008
pubmed: 23932312
Karsdal MA, et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum. 2012;42(2):131–9. https://doi.org/10.1016/j.semarthrit.2012.01.004 .
doi: 10.1016/j.semarthrit.2012.01.004
pubmed: 22397953
Siebuhr AS, et al. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther. 2013;15(4):R86. https://doi.org/10.1186/ar4266 .
doi: 10.1186/ar4266
pubmed: 23945134
pmcid: 3978450
Bay-Jensen AC, Platt A, Siebuhr AS, Christiansen C, Byrjalsen I, Karsdal MA. Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study. Arthritis Res Ther. 2016;18(1):13. https://doi.org/10.1186/s13075-015-0913-x .
doi: 10.1186/s13075-015-0913-x
pubmed: 26787505
pmcid: 4719735
Cescon M, et al. Collagen VI at a glance. J Cell Sci. 2015;128(19):3525–31. https://doi.org/10.1242/jcs.169748 .
doi: 10.1242/jcs.169748
pubmed: 26377767
Gara SK, et al. Differential and restricted expression of novel collagen VI chains in mouse. Matrix Biol. 2011;30(4):248–57. https://doi.org/10.1016/j.matbio.2011.03.006 .
doi: 10.1016/j.matbio.2011.03.006
pubmed: 21477648
Kuo HJ, Maslen CL, Keene DR, Glanville RW. Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J Biol Chem. 1997;272(42):26522–9. https://doi.org/10.1074/jbc.272.42.26522 .
doi: 10.1074/jbc.272.42.26522
pubmed: 9334230
Groulx JF, Gagné D, Benoit YD, Martel D, Basora N, Beaulieu JF. Collagen VI is a basement membrane component that regulates epithelial cell-fibronectin interactions. Matrix Biol. 2011;30(3):195–206. https://doi.org/10.1016/j.matbio.2011.03.002 .
doi: 10.1016/j.matbio.2011.03.002
pubmed: 21406227
Karsdal MA, et al. Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther. 2014;40(3):233–49. https://doi.org/10.1111/apt.12820 .
doi: 10.1111/apt.12820
pubmed: 24909260
Alexopoulos LG, Youn I, Bonaldo P, Guilak F. Developmental and osteoarthritic changes in Col6a1 -knockout mice: biomechanics of type VI collagen in the cartilage pericellular matrix. Arthritis Rheum. 2009;60(3):771–9. https://doi.org/10.1002/art.24293 .
doi: 10.1002/art.24293
pubmed: 19248115
pmcid: 2724839
Zelenski NA, Leddy HA, Sanchez-Adams J, Zhang J, Bonaldo P, Liedtke W, Guilak F. Type VI collagen regulates pericellular matrix properties, chondrocyte swelling, and mechanotransduction in mouse articular cartilage. Arthritis Rheumatol. 2015;67(5):1286–94. https://doi.org/10.1177/0963721412473755.Surging .
doi: 10.1177/0963721412473755.Surging
pubmed: 25604429
pmcid: 4414817
Bonaldo P, Russo V, Bucciotti F, Doliana R, Colombatti A. Structural and functional features of the alpha 3 chain indicate a bridging role for chicken collagen VI in connective tissues. Biochemistry. 1990;29(5):1245–54. Available: http://www.ncbi.nlm.nih.gov/pubmed/2322559 .
doi: 10.1021/bi00457a021
pubmed: 2322559
Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R, Hook M. Binding of the proteoglycan decorin to collagen type VI. J Biol Chem. 1992;267(8):5250–6.
doi: 10.1016/S0021-9258(18)42759-7
pubmed: 1544908
Wiberg C, et al. Biglycan and decorin bind close to the N-terminal region of the collagen VI triple helix. J Biol Chem. 2001;276(22):18947–52. https://doi.org/10.1074/jbc.M100625200 .
doi: 10.1074/jbc.M100625200
pubmed: 11259413
Wu JJ, Eyre DR, Slayter HS. Type VI collagen of the intervertebral disc. Biochemical and electron-microscopic characterization of the native protein. Biochem J. 1987;248(2):373–81. Available: http://www.ncbi.nlm.nih.gov/pubmed/3124811 .
doi: 10.1042/bj2480373
pubmed: 3124811
pmcid: 1148551
Smeriglio P, et al. Collagen VI enhances cartilage tissue generation by stimulating chondrocyte proliferation. Tissue Eng Part A. 2015;21(3–4):840–9. https://doi.org/10.1089/ten.tea.2014.0375 .
doi: 10.1089/ten.tea.2014.0375
pubmed: 25257043
Wolf J, Carsons SE. Distribution of type VI collagen expression in synovial tissue and cultured synoviocytes: relation to fibronectin expression. Ann Rheum Dis. 1991;50(7):493–6. https://doi.org/10.1136/ard.50.7.493 .
doi: 10.1136/ard.50.7.493
pubmed: 1877856
pmcid: 1004465
Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11(1 P.447-888):529–43. https://doi.org/10.2741/1817 .
doi: 10.2741/1817
pubmed: 16146751
Itoh Y. Metalloproteinases in rheumatoid arthritis: potential therapeutic targets to improve current therapies. Prog Mol Biol Transl Sci. 2017;148:327–38. https://doi.org/10.1016/bs.pmbts.2017.03.002 . Elsevier B.V.
doi: 10.1016/bs.pmbts.2017.03.002
pubmed: 28662826
Barascuk N, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43(10–11):899–904. https://doi.org/10.1016/j.clinbiochem.2010.03.012 .
doi: 10.1016/j.clinbiochem.2010.03.012
pubmed: 20380828
Bihlet AR, et al. Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD. Respir Res. 2017;18(1):22. https://doi.org/10.1186/s12931-017-0509-x .
doi: 10.1186/s12931-017-0509-x
pubmed: 28103932
pmcid: 5248528
Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int. 2012;32(11):3565–72. https://doi.org/10.1007/s00296-011-2237-8 .
doi: 10.1007/s00296-011-2237-8
pubmed: 22086471
Fleischmann RM, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol. 2013;40(2):113–26. https://doi.org/10.3899/jrheum.120447 .
doi: 10.3899/jrheum.120447
pubmed: 23322466
Smolen JS, Avila JCM, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012;71(5):687–93. https://doi.org/10.1136/annrheumdis-2011-200395 .
doi: 10.1136/annrheumdis-2011-200395
pubmed: 22121130
Veidal SS, et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis - identification and validation of a novel biochemical marker assay. PLoS One. 2011;6(9):1–9. https://doi.org/10.1371/journal.pone.0024753 .
doi: 10.1371/journal.pone.0024753
Kremer JM, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu. Arthritis Rheum. 2011;63(3):609–21. https://doi.org/10.1002/art.30158 .
doi: 10.1002/art.30158
pubmed: 21360490
Gudmann NS, Hirata S, Karsdal MA, Kubo S, Bay-Jensen A-C, Tanaka Y. Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients. Clin Exp Rheumatol. 36(3):462–470. Available: http://www.ncbi.nlm.nih.gov/pubmed/29465351 . Accessed 31 Oct 2019.
Juhl P, Thudium CS, Gudmann NS, Karsdal MA, Bay-Jensen A-C, Siebuhr AS. IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE. Clin Exp Rheumatol. 36(4):568–574. Available: http://www.ncbi.nlm.nih.gov/pubmed/29465346 .
Gudmann NS, et al. Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis. Clin Exp Rheumatol. 2018. Available: http://www.ncbi.nlm.nih.gov/pubmed/29745884 .
Thudium CS, et al. The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):1–11. https://doi.org/10.1186/s13075-020-02340-7 .
doi: 10.1186/s13075-020-02340-7
Bay-Jensen AC, et al. Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. BMC Rheumatol. 2019;3(1). https://doi.org/10.1186/s41927-019-0052-0 .
Bay-Jensen AC, Byrjalsen I, Siebuhr AS, Christiansen C, Platt A, Karsdal MA. Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline. J Clin Rheumatol. 2014;20(6):332–5. https://doi.org/10.1097/RHU.0000000000000150 .
doi: 10.1097/RHU.0000000000000150
pubmed: 25160020
pmcid: 4154839
von der Mark H, Aumailley M, Wick G, Fleischmajer R, Timpl R. Immunochemistry, genuine size and tissue localization of collagen VI. Eur J Biochem. 1984;142(3):493–502. https://doi.org/10.1111/j.1432-1033.1984.tb08313.x .
doi: 10.1111/j.1432-1033.1984.tb08313.x
pubmed: 6432530
Okada Y, et al. localization of type VI collagen in the lining cell layer of normal and rheumatoid synovium. Lab Invest. 1990;63(5):647–56. Available: http://www.ncbi.nlm.nih.gov/pubmed/2232713 .
pubmed: 2232713